ReviR Therapeutics Raises $30M Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders July 30, 2024
ReviR Therapeutics Raises $30M Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders July 30, 2024